The PORTEC-3 trial demonstrated that molecular classification of high-risk endometrial cancer has strong prognostic value, with adjuvant chemoradiotherapy significantly improving recurrence-free survival in p53 abnormal tumors, highlighting the need for molecular-based risk stratification. Here, TP53 is linked to endometrial cancer.